# ADJUVANT DEVELOPMENT PROGRAM - COVID-19 Supplement

> **NIH NIH N01** · VIROVAX LLC · 2020 · $649,995

## Abstract

This study will test a novel antiviral compound (kinase inhibitor) in SARS-CoV2 infected cells.  
This compound has been shown to inhibit flaviviruses and  other CoVs  (SARS and MERS).

## Key facts

- **NIH application ID:** 10285318
- **Project number:** 272201800049C-P00003-9999-2
- **Recipient organization:** VIROVAX LLC
- **Principal Investigator:** SUNIL DAVID
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $649,995
- **Award type:** —
- **Project period:** 2018-09-30 → 2023-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10285318

## Citation

> US National Institutes of Health, RePORTER application 10285318, ADJUVANT DEVELOPMENT PROGRAM - COVID-19 Supplement (272201800049C-P00003-9999-2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10285318. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*